These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 25914912)

  • 1. Effectiveness of opioid analgesics in chronic noncancer pain.
    Ferrari R; Zanolin ME; Duse G; Visentin M
    Pain Pract; 2015 Mar; 15(3):272-8. PubMed ID: 25914912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study.
    Gálvez R; Schäfer M; Hans G; Falke D; Steigerwald I
    Adv Ther; 2013 Mar; 30(3):229-59. PubMed ID: 23475406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Long-term opioid therapy in chronic noncancer pain. A systematic review and meta-analysis of efficacy, tolerability and safety in open-label extension trials with study duration of at least 26 weeks].
    Häuser W; Bernardy K; Maier C
    Schmerz; 2015 Feb; 29(1):96-108. PubMed ID: 25503691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Tapentadol prolonged release improves analgesia, functional impairment and quality of life in patients with chronic pain who have previously received oxycodone/naloxone].
    Kern KU; Krings D; Waldmann-Rex S
    MMW Fortschr Med; 2014 Jul; 156 Suppl 2():54-63. PubMed ID: 25351028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and tolerability of transdermal buprenorphine patches: a multicenter, prospective, open-label study in Asian patients with moderate to severe chronic musculoskeletal pain.
    Yoon DH; Bin SI; Chan SK; Chung CK; In Y; Kim H; Lichauco JJ; Mok CC; Moon YW; Ng TK; Penserga EG; Shin DA; You D; Moon H
    BMC Musculoskelet Disord; 2017 Aug; 18(1):337. PubMed ID: 28778219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Budget impact analysis of tapentadol extended release for the treatment of moderate to severe chronic noncancer pain.
    Merchant S; Noe LL; Howe A; Duff S; Gricar J; Ogden K; Mody SH
    Clin Ther; 2013 May; 35(5):659-72. PubMed ID: 23587608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tapentadol prolonged release for severe chronic pain. Results of a non-interventional study involving general practitioners and internists].
    Schwittay A; Schumann C; Litzenburger BC; Schwenke K
    MMW Fortschr Med; 2012 Oct; 154 Suppl 3():85-93. PubMed ID: 23133884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic review of tapentadol in chronic severe pain.
    Riemsma R; Forbes C; Harker J; Worthy G; Misso K; Schäfer M; Kleijnen J; Stürzebecher S
    Curr Med Res Opin; 2011 Oct; 27(10):1907-30. PubMed ID: 21905968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of Fentanyl Patch for Treatment of Moderate-to-severe Chronic Noncancer Pain: Postmarketing Surveillance of Medical Practice in Japan Using a Risk Minimization Action Plan.
    Kawai K; Yoshizawa K; Fujie M; Kobayashi H; Ogawa Y; Yajima T
    Pain Pract; 2017 Feb; 17(2):239-248. PubMed ID: 27080988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine.
    Daitch J; Frey ME; Silver D; Mitnick C; Daitch D; Pergolizzi J
    Pain Physician; 2012 Jul; 15(3 Suppl):ES59-66. PubMed ID: 22786462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attitudes Toward Opioids and Risk of Misuse/Abuse in Patients with Chronic Noncancer Pain Receiving Long-term Opioid Therapy.
    Vargas-Schaffer G; Cogan J
    Pain Med; 2018 Feb; 19(2):319-327. PubMed ID: 28340165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An evaluation of the predictive validity of the Pain Medication Questionnaire with a heterogeneous group of patients with chronic pain.
    Dowling LS; Gatchel RJ; Adams LL; Stowell AW; Bernstein D
    J Opioid Manag; 2007; 3(5):257-66. PubMed ID: 18181380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of the Opioid Compliance Checklist to Monitor Chronic Pain Patients Receiving Opioid Therapy in Primary Care.
    Jamison RN; Martel MO; Huang CC; Jurcik D; Edwards RR
    J Pain; 2016 Apr; 17(4):414-23. PubMed ID: 26705974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation and usefulness of the Danish version of the Pain Medication Questionnaire in opioid-treated chronic pain patients.
    Højsted J; Nielsen PR; Kendall S; Frich L; Sjøgren P
    Acta Anaesthesiol Scand; 2011 Nov; 55(10):1231-8. PubMed ID: 22092128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of tapentadol prolonged release compared with oxycodone controlled release in the UK in patients with severe non-malignant chronic pain who failed 1st line treatment with morphine.
    Ikenberg R; Hertel N; Moore RA; Obradovic M; Baxter G; Conway P; Liedgens H
    J Med Econ; 2012; 15(4):724-36. PubMed ID: 22364286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tapentadol prolonged release for severe chronic pain: results of a noninterventional study involving general practitioners and internists.
    Schwittay A; Schumann C; Litzenburger BC; Schwenke K
    J Pain Palliat Care Pharmacother; 2013 Aug; 27(3):225-34. PubMed ID: 23957433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-relevant outcomes and health-related quality of life in patients with chronic, severe, noncancer pain treated with tapentadol prolonged release-Using criteria of health technology assessment.
    Hofmann JF; Lal A; Steffens M; Boettger R
    J Opioid Manag; 2016; 12(5):323-331. PubMed ID: 27844472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tapentadol prolonged release for the treatment of severe chronic tumor pain in routine clinical practice].
    Agbalaka A; Schwenke K; Litzenburger B
    MMW Fortschr Med; 2012 Dec; 154 Suppl 4():123-30. PubMed ID: 23326931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Conversion to tapentadol PR improves analgesia and quality of life in patients with severe and chronic pain despite using tramadol > 300 mg/d].
    Richter U; Waldmann-Rex S; Lehmann U
    Wien Klin Wochenschr; 2015 Jun; 127(11-12):477-87. PubMed ID: 25409951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.